KR20220160170A - Composition for improving memory and cognitive ability, comprising Salvia officinalis L. extract and Hypericum perforatum L. extract - Google Patents
Composition for improving memory and cognitive ability, comprising Salvia officinalis L. extract and Hypericum perforatum L. extract Download PDFInfo
- Publication number
- KR20220160170A KR20220160170A KR1020210067972A KR20210067972A KR20220160170A KR 20220160170 A KR20220160170 A KR 20220160170A KR 1020210067972 A KR1020210067972 A KR 1020210067972A KR 20210067972 A KR20210067972 A KR 20210067972A KR 20220160170 A KR20220160170 A KR 20220160170A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- sage
- improving memory
- cognitive ability
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000003930 cognitive ability Effects 0.000 title claims description 10
- 230000007087 memory ability Effects 0.000 title claims description 10
- 235000017309 Hypericum perforatum Nutrition 0.000 title abstract description 4
- 244000141009 Hypericum perforatum Species 0.000 title abstract description 4
- 240000007164 Salvia officinalis Species 0.000 title abstract description 4
- 235000002912 Salvia officinalis Nutrition 0.000 title abstract description 4
- 239000001296 salvia officinalis l. Substances 0.000 title description 23
- 235000002020 sage Nutrition 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 235000002566 Capsicum Nutrition 0.000 claims description 21
- 239000006002 Pepper Substances 0.000 claims description 17
- 241000722363 Piper Species 0.000 claims description 17
- 235000016761 Piper aduncum Nutrition 0.000 claims description 17
- 235000017804 Piper guineense Nutrition 0.000 claims description 17
- 235000008184 Piper nigrum Nutrition 0.000 claims description 17
- 235000020752 sage extract Nutrition 0.000 claims description 17
- 229940112950 sage extract Drugs 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 240000003291 Armoracia rusticana Species 0.000 claims description 8
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000001390 capsicum minimum Substances 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 229940116257 pepper extract Drugs 0.000 claims description 2
- 240000008574 Capsicum frutescens Species 0.000 claims 2
- 230000015654 memory Effects 0.000 abstract description 16
- 210000002569 neuron Anatomy 0.000 abstract description 13
- 230000003920 cognitive function Effects 0.000 abstract description 12
- 210000004556 brain Anatomy 0.000 abstract description 11
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract description 10
- 229940022698 acetylcholinesterase Drugs 0.000 abstract description 10
- 230000003078 antioxidant effect Effects 0.000 abstract description 8
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 9
- 206010012289 Dementia Diseases 0.000 description 9
- 239000002131 composite material Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 240000004160 Capsicum annuum Species 0.000 description 7
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 7
- 235000007862 Capsicum baccatum Nutrition 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 239000001728 capsicum frutescens Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 5
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 5
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 206010027175 memory impairment Diseases 0.000 description 5
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 5
- 229960002646 scopolamine Drugs 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- -1 Methylhydroxy Chemical group 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000006386 memory function Effects 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000208293 Capsicum Species 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 235000017186 Celastrus paniculatus Nutrition 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 240000003098 Embelia ribes Species 0.000 description 1
- 235000018436 Embelia ribes Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 기억력 및/또는 인지 기능 개선용 조성물에 관한 것으로, 구체적으로는 세이지 추출물 및 서양고추나물 추출물을 포함하는 기억력 및/또는 인지 기능 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving memory and/or cognitive function, and specifically relates to a composition for improving memory and/or cognitive function comprising a sage extract and a horseradish extract.
치매는 일반적으로 인간의 인지기능, 지적능력, 감정 및 행동변화 등에서 뚜렷한 손상을 나타내는 복합 임상 증후군으로서, 기억력, 주의력, 언어기능, 시공간 능력 등의 대뇌피질 기능장애가 발생하여 일상, 사회생활을 영위하는데 큰 어려움을 겪게 되는 상태이다. 치매라고 정의할 때는 기억력을 포함하여 다른 인지기능 중 한 가지 이상의 장애가 있는 경우를 말하며, 단순히 기억력만 떨어진 경우는 치매라고 하지 않는다.Dementia is a complex clinical syndrome that generally shows clear impairment in human cognitive function, intellectual ability, emotional and behavioral changes, etc. It is a state of great difficulty. Dementia is defined as a case of one or more impairments among other cognitive functions, including memory.
치매의 원인으로는 퇴행성 뇌질환인 알츠하이머나 파킨슨병으로부터 뇌출혈, 대사성질환인 간성뇌병증, 윌슨병(Wilson's Disease), 감염성 질환인 신경매독, 후천성면역결핍증, 알코올과 같은 약물중독, 뇌외상 등 다양한 병인이 있으며, 어떤 형태로는 중추신경계에 구조적, 기능적 이상을 초래할 수 있는 질환은 치매를 유발할 수가 있다. 그 중에서도 알츠하이머병에 의한 치매가 50 내지 60 %로 가장 많으며, 뇌혈관 질환에 의한 치매가 그 다음이다.Dementia can be caused by various causes such as degenerative brain diseases such as Alzheimer's or Parkinson's disease, cerebral hemorrhage, metabolic diseases such as hepatic encephalopathy, Wilson's disease, infectious diseases such as neurosyphilis, acquired immunodeficiency syndrome, drug addiction such as alcohol, and brain trauma. In some forms, diseases that can lead to structural and functional abnormalities in the central nervous system can lead to dementia. Among them, dementia caused by Alzheimer's disease is the most common at 50 to 60%, followed by dementia caused by cerebrovascular disease.
기억 인지 장애는 알츠하이머 질환자들이 처음으로 겪는 증상이며 또한 가장 흔한 증상이다. 알츠하이머병의 초기에 환자들은 최근의 대화나 일의 내용을 자세하게 기억하지 못하는 최근 기억(recent memory) 장애를 겪게 되는데, 이는 해마의 신경세포가 손상되어 최근 기억을 저장하는 기능이 떨어진 데에서 기인한다. 하지만 이 시기에는 먼 과거에 있었던 사건들에 대한 과거 기억은 상대적으로 잘 유지된다. 그러나 병이 점차 진행됨에 따라 장기기억의 저장과 관련된 대뇌피질이 손상되면서 이러한 과거의 기억도 점차 장애를 보이게 된다.Memory and cognitive impairment is the first and most common symptom experienced by people with Alzheimer's disease. In the early stages of Alzheimer's disease, patients suffer from recent memory impairment, which prevents them from remembering details of recent conversations or work. . However, during this time, past memories of events in the distant past are relatively well maintained. However, as the disease progresses, the cerebral cortex involved in the storage of long-term memories is damaged, and these memories of the past gradually become impaired.
현재 우리나라의 알츠하이머병 치료제의 경우 외국계열 회사가 98 %의 점유율을 차지하고 있을 정도로 수입에 의존하는 바가 크다. 더욱이 한 회사가 시장의 80%를 차지하고 있어 사실상 독점하고 있다고 볼 수 있다. 이는 국가경쟁력 측면에서도 치매 치료분야의 성장이 시급함을 알 수 있다. 따라서 부작용이 적으면서 효과적인 항건망증 제제 및 기억력 개선제의 개발은 알츠하이머 질환자의 삶의 질 향상과 초기 병증 개선 및 치료에 상당한 도움을 줄 수 있으며, 또한 기억 인지력의 장애를 겪는 건망증, 치매환자에게도 도움을 줄 수 있을 것으로 사료된다.Currently, in the case of Alzheimer's disease treatment in Korea, foreign companies are heavily dependent on imports, with 98% of the market share. Moreover, one company has 80% of the market, so it can be seen as a virtual monopoly. This shows that the growth of the dementia treatment field is urgent in terms of national competitiveness. Therefore, the development of effective anti-amnesia agents and memory improvers with few side effects can significantly help improve the quality of life and improve and treat early symptoms of Alzheimer's disease patients, and also help patients with amnesia and dementia who suffer from memory and cognitive impairment. It is believed that it can give
한편, 세이지와 고추나물은 산업적으로 건강기능식품 기능성 원료 또는 약학 원료로 알려져 있다. 특히 세이지는 근육질환 치료용, 고추나물은 항당뇨용에 대한 선행기술이 공지되어 있으나 이들 두 식물이 신경계에 미치는 영향에 대해서는 알려진 바가 없다.On the other hand, sage and pepper sprouts are industrially known as functional raw materials for health functional foods or pharmaceutical raw materials. In particular, prior art for sage for the treatment of muscle diseases and red pepper herb for antidiabetic use is known, but the effects of these two plants on the nervous system are unknown.
상기와 같은 배경 하에 본 발명은 세이지와 서양고추나물의 기억력 개선, 인지기능 증진 효과가 우수함을 확인함으로써 본 발명을 완성하였다.Under the above background, the present invention was completed by confirming that sage and western pepper herbs are excellent in improving memory and enhancing cognitive function.
따라서 본 발명은 세이지 추출물 및 서양고추나물 추출물을 포함하는 기억력 개선 또는 인지기능 개선용 조성물을 제공하고자 한다.Therefore, the present invention is to provide a composition for improving memory or cognitive function comprising a sage extract and a western pepper extract.
상기와 같은 목적을 달성하기 위해 본 발명은 세이지 추출물 및 서양고추나물 추출물을 포함하는 기억력 개선 또는 인지기능 증진용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for improving memory or enhancing cognitive function comprising a sage extract and a western pepper herb extract.
또한, 세이지 추출물 및 서양고추나물 추출물을 포함하는 항염증용 조성물을 제공한다.In addition, an anti-inflammatory composition comprising a sage extract and a horseradish extract is provided.
또한, 세이지 추출물 및 서양고추나물 추출물을 포함하는 항산화용 조성물을 제공한다.In addition, an antioxidant composition comprising a sage extract and a horseradish extract is provided.
상기 세이지(Salvia officinalis L.) 추출물은 세이지의 꽃, 잎, 줄기, 뿌리 등으로부터 추출된 것일 수 있고, 바람직하게는 세이지의 잎로부터 추출된 추출물일 수 있으나 이에 제한되는 것은 아니다.The sage (Salvia officinalis L.) extract may be extracted from sage flowers, leaves, stems, roots, etc., and may preferably be an extract extracted from sage leaves, but is not limited thereto.
상기 서양고추 나물(Hypericum perforatum L.) 추출물은 서양고추 나물의 꽃, 잎, 열매, 뿌리, 줄기 등으로부터 추출된 것일 수 있고, 바람직하게는 서양고추 나물의 꽃, 잎, 열매로부터 추출된 추출물일 수 있으나 이에 제한되는 것은 아니다.The western pepper herb (Hypericum perforatum L.) extract may be extracted from flowers, leaves, fruits, roots, stems, etc. of western pepper herbs, preferably an extract extracted from flowers, leaves, and fruits of western pepper herbs. It can be, but is not limited thereto.
본 발명에서의 상기 세이지 또는 서양고추나물은 건조되지 않은 상태, 건조된 상태, 건조 후 분쇄된 상태 등일 수 있으나 이에 제한되는 것은 아니다.The sage or capsicum herb in the present invention may be in an undried state, a dried state, or a dried and then pulverized state, but is not limited thereto.
상기 세이지(Salvia officinalis) 추출물 또는 서양고추나물(Hypericum perforatum L.) 추출물은 물, 에탄올과 같은 극성 용매 또는 유기 용매를 사용하여 추출될 수 있으나, 바람직하게는 물, 에탄올을 사용하여 추출될 수 있고, 더욱 바람직하게는 50 내지 90%(v/v) 의 발효주정, 더욱 바람직하게는 60 내지 80%(v/v) 의 발효주정을 사용하여 추출할 수 있으나 이에 제한되는 것은 아니다.The sage ( Salvia officinalis ) extract or western pepper herb ( Hypericum perforatum L. ) extract may be extracted using a polar solvent or organic solvent such as water or ethanol, but may be preferably extracted using water or ethanol, , More preferably, 50 to 90% (v / v) of fermented alcohol, more preferably 60 to 80% (v / v) of fermented alcohol can be used for extraction, but is not limited thereto.
또한, 상기 세이지 추출물 및 서양고추나물 추출물은 1 : 1 내지 5, 바람직하게는 1 : 1 내지 3, 더욱 바람직하게는 1 : 1의 중량비로 포함될 수 있으나 이에 제한되는 것은 아니다.In addition, the sage extract and the western pepper herb extract may be included in a weight ratio of 1: 1 to 5, preferably 1: 1 to 3, and more preferably 1: 1, but are not limited thereto.
상기 세이지 추출물과 서양고추 나물 추출물은 40 내지 80℃, 바람직하게는 50 내지 70℃, 더욱 바람직하게는 60℃에서 1 내지 3시간, 바람직하게는 2시간 동안 추출될 수 있다. 상기 온도 및 시간 미만으로 추출할 경우 유효성분이 잘 추출되지 않을 수 있고, 상기 온도 및 시간을 초과하여 추출할 경우, 유효성분이 파괴될 수 있다.The sage extract and the western pepper herb extract may be extracted at 40 to 80°C, preferably 50 to 70°C, more preferably 60°C for 1 to 3 hours, preferably 2 hours. When extracted below the temperature and time, the active ingredient may not be well extracted, and when extracted above the temperature and time, the active ingredient may be destroyed.
본 발명에서 용어 "기억" 또는 "기억력"은 주위 환경으로부터 얻은 새로운 정보나 학습된 경험, 지식을 습득하여 뇌의 특정부위에 부호화하여 저장하고 이를 다시 회상할 수 있는 능력을 의미한다. 본 발명의 조성물은 상기 와 같은 기억력을 개선시킬 수 있는 효과가 있으며, 이러한 효과에는 정상인의 기억력을 증진시키는 효과뿐만 아니라 손상된 기억력 또는 기억력 장애를 회복시키는 모든 효과를 포함할 수 있다. 또한, 상기 기억력 장애는 외상, 주의력 결핍, 노화, 질병 등의 다양한 원인에 의하여 상기 기억력이 정상인에 비해 낮아진 상태를 의미하며, 건망증, 집중력 장애, 공간지각력 손실, 학습능력의 둔화, 인지력 상실 등을 포함하는 개념이다.In the present invention, the term "memory" or "memory" refers to the ability to acquire new information, learned experience, or knowledge obtained from the surrounding environment, encode and store them in a specific part of the brain, and recall them again. The composition of the present invention has the effect of improving memory as described above, and this effect may include all effects of restoring damaged memory or memory impairment as well as the effect of enhancing memory of normal people. In addition, the memory impairment refers to a state in which the memory is lowered than that of a normal person due to various causes such as trauma, attention deficit, aging, disease, etc. It is a concept that includes
본 발명에서 "인지기능"은 지식과 정보를 효율적으로 조작하는 능력으로서, 본 발명의 목적상 인지기능 장애는 상기와 같은 인지기능이 저하되어 생기는 상태, 그에 따른 질환, 그를 증상으로 하는 모든 질환을 포함할 수 있는 개념으로, 바람직하게는 뇌 신경세포의 손상으로 발생하는 장애를 의미할 수 있다. 본 발명의 인지기능 장애에는 건망증, 알츠하이머병, 혈관성 치매, 두부손상에 의한 치매 또는 파킨슨병 등이 포함될 수 있으나 이에 제한되는 것은 아니다.In the present invention, "cognitive function" is the ability to efficiently manipulate knowledge and information, and for the purpose of the present invention, cognitive dysfunction refers to a condition caused by a decrease in cognitive function, a disease resulting therefrom, and all diseases having such a symptom. As a concept that can be included, it may preferably mean a disorder caused by damage to brain nerve cells. Cognitive dysfunction of the present invention may include, but is not limited to, amnesia, Alzheimer's disease, vascular dementia, dementia due to head injury, or Parkinson's disease.
상기 기억력 개선 또는 인지기능 증진용 조성물은 약학적 조성물 또는 식품 조성물 중 어느 하나일 수 있다.The composition for improving memory or enhancing cognitive function may be any one of a pharmaceutical composition or a food composition.
상기 항염증 조성물은 염증의 예방, 개선 또는 치료용 약학적 조성물 또는 염증의 예방 또는 개선용 화장료 조성물 또는 염증의 예방 또는 개선용 식품 조성물일 수 있다.The anti-inflammatory composition may be a pharmaceutical composition for preventing, improving or treating inflammation or a cosmetic composition for preventing or improving inflammation or a food composition for preventing or improving inflammation.
본 발명에서의 염증 질환은 아토피 피부염, 여드름, 건선, 부비동염, 비염, 결막염, 천식, 피부염, 사구체신염, 뇌염, 염증성 장염, 과민성 대장 증후군, 만성 폐쇄성 폐질환, 패혈증, 패혈성 쇼크증, 바이러스 또는 박테리아 감염에 의한 만성 염증 질환 등을 포함할 수 있으나, 이에 제한되는 것은 아니다.Inflammatory disease in the present invention is atopic dermatitis, acne, psoriasis, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, glomerulonephritis, encephalitis, inflammatory enteritis, irritable bowel syndrome, chronic obstructive pulmonary disease, sepsis, septic shock, virus or Chronic inflammatory diseases caused by bacterial infections may be included, but are not limited thereto.
상기 항산화용 조성물은 항산화용 식품 조성물 또는 항산화용 화장료 조성물일 수 있다.The antioxidant composition may be a food composition for antioxidant or a cosmetic composition for antioxidant.
상기 항산화는 산화를 방지하는 모든 작용을 의미할 수 있다. 구체적으로, 활성산소종(ROS) 제거, ABTS 및 DPPH 자유 라디칼 소거, 산화질소 생성 억제 작용 등을 포함할 수 있으나, 이에 제한되는 것은 아니다.The antioxidant may mean any action that prevents oxidation. Specifically, it may include reactive oxygen species (ROS) removal, ABTS and DPPH free radical scavenging, nitric oxide production inhibition, etc., but is not limited thereto.
본 발명에서의 약학적 조성물은 세이지 추출물 및 서양고추나물 추출물을 10ug/mg 이상, 바람직하게는 100ug/mg 이상, 더욱 바람직하게는 200ug/mg 이상, 더욱 바람직하게는 400ug/mg 이상의 농도로 포함할 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition of the present invention may contain the sage extract and the horseradish extract at a concentration of 10 ug/mg or more, preferably 100 ug/mg or more, more preferably 200 ug/mg or more, and still more preferably 400 ug/mg or more. It may be, but is not limited thereto.
또한, 상기 약학적 조성물은 약학적으로 허용되는 담체, 결합제, 활탁제, 붕해제, 부형제, 가용화제, 분산제, 안정화제, 현탁화제 등을 추가적으로 더 포함할 수 있고, 예를 들면 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 알지네이트, 칼슘 포스페이트, 칼슘 실리케이트, 말토덱스트린, 이산화규소, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 등일 수 있으나 이에 제한되는 것은 아니다.In addition, the pharmaceutical composition may further include a pharmaceutically acceptable carrier, binder, lubricant, disintegrant, excipient, solubilizer, dispersant, stabilizer, suspending agent, etc., for example, lactose, dex Trose, Sucrose, Sorbitol, Mannitol, Xylitol, Erythritol, Maltitol, Starch, Alginate, Calcium Phosphate, Calcium Silicate, Maltodextrin, Silicon Dioxide, Cellulose, Methyl Cellulose, Microcrystalline Cellulose, Polyvinylpyrrolidone, Methylhydroxy It may be benzoate, propylhydroxybenzoate, talc, magnesium stearate, etc., but is not limited thereto.
또한, 상기 약학 조성물은 당 업계에서 제제화에 통상적으로 사용되는 방법으로 정제, 캡슐, 서방형 제제, 엘릭서, 서스펜션, 시럽, 웨이퍼, 단위 투약 주사제 앰플, 현탁액 등의 제형으로 제조될 수 있다.In addition, the pharmaceutical composition may be prepared in a formulation such as a tablet, capsule, sustained-release preparation, elixir, suspension, syrup, wafer, unit dose injection ampoule, suspension, etc. by a method commonly used for formulation in the art.
상기 약학 조성물의 투여 방식은 경구 투여, 정맥내 투여, 근육내 투여, 동맥내 투여, 골수내 투여, 경막내 투여, 심장내 투여, 경피 투여, 피하 투여, 복강내 투여, 비강내 투여, 장관 투여, 구강 및 설하는 포함하는 국소 투여, 직장 투여, 국소 투여, 진피 투여, 점막 투여, 척추내 투여 등의 방법으로 투여될 수 있고, 바람직하게는 경구 투여일 수 있으나, 이에 제한되는 것은 아니다. 또한, 상기 투여 시 각 투여 방식에 절절한 제형으로 제제화되어 투여될 수 있으며, 제제화는 당 업계에서 널리 알려져 있는 방법으로 제제화될 수 있다.The administration method of the pharmaceutical composition is oral administration, intravenous administration, intramuscular administration, intraarterial administration, intramedullary administration, intrathecal administration, intracardiac administration, transdermal administration, subcutaneous administration, intraperitoneal administration, intranasal administration, enteral administration , It may be administered by methods such as topical administration, rectal administration, topical administration, dermal administration, mucosal administration, intravertebral administration, including oral and sublingual administration, preferably oral administration, but is not limited thereto. In addition, at the time of administration, it may be formulated and administered in a formulation suitable for each administration method, and the formulation may be formulated by a method widely known in the art.
상기 약학 조성물은 투여 대상의 연령, 체중, 건강 상태, 성별, 투여시간, 투여 경로, 배출율, 유효성분의 함량, 예방 또는 치료될 특정 질환의 중증도 등에 따라 적절하게 선택될 수 있고, 투여 횟수는 1일 1회 또는 2회, 격일마다, 격주마다, 격월 등의 방식으로 투여할 수 있다.The pharmaceutical composition may be appropriately selected according to the age, weight, health condition, sex, administration time, administration route, excretion rate, active ingredient content, severity of a specific disease to be prevented or treated, etc., and the number of administrations is 1 It may be administered once or twice a day, every other day, every other week, or every other month.
상기 화장료 조성물은 화장료 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 용매, 안정화제, 용해화제, 유화제, 비타민, 향료와 같은 통상적인 보조제, 담체 등을 추가적으로 더 포함할 수 있다.The cosmetic composition includes components commonly used in cosmetic compositions, and may additionally include conventional adjuvants such as solvents, stabilizers, solubilizers, emulsifiers, vitamins, and fragrances, carriers, and the like.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 화장수, 영양로션, 영양크림, 영양에센스, 팩, 파운데이션, 바디오일, 헤어오일, 샴푸, 린스 등의 제형으로 제조될 수 있으나 이에 제한되는 것은 아니다.The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art. For example, it may be manufactured in formulations such as lotion, nutrient lotion, nutrient cream, nutrient essence, pack, foundation, body oil, hair oil, shampoo, rinse, etc., but is not limited thereto.
상기 식품 조성물은 당 업계에서 식품을 제조하기 위해 통상적으로 사용하는 향미제, 풍미제, 안정화제, 증점제, 방부제 등을 추가적으로 더 포함할 수 있고, 예를 들면 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 알지네이트, 칼슘 포스페이트, 칼슘 실리케이트, 말토덱스트린, 이산화규소, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 등일 수 있으나 이에 제한되는 것은 아니다.The food composition may additionally include flavoring agents, flavoring agents, stabilizers, thickeners, preservatives, etc., which are commonly used in the art to prepare food, for example, lactose, dextrose, sucrose, Sorbitol, Mannitol, Xylitol, Erythritol, Maltitol, Starch, Alginate, Calcium Phosphate, Calcium Silicate, Maltodextrin, Silicon Dioxide, Cellulose, Methyl Cellulose, Microcrystalline Cellulose, Polyvinylpyrrolidone, Methylhydroxybenzoate, Propylhydroxy It may be benzoate, talc, magnesium stearate, etc., but is not limited thereto.
상기 식품 조성물은 음료, 껌, 차, 비타민 복합제, 분말, 과립, 정제, 캡슐,과자, 등의 형태로 제조될 수 있다. The food composition may be prepared in the form of beverages, gum, tea, vitamin complexes, powders, granules, tablets, capsules, confectionery, and the like.
상기 식품 조성물은 섭취 대상의 연령, 체중, 건강 상태, 성별, 투여시간, 유효성분의 함량, 질환의 중증도 등에 따라 적절하게 선택될 수 있고, 섭취 횟수는 1일 1회 또는 2회, 격일마다, 격주마다, 격월 등의 방식으로 섭취할 수 있다.The food composition may be appropriately selected according to the age, weight, health condition, sex, administration time, content of the active ingredient, severity of the disease, etc. of the subject to be consumed, and the number of intakes is once or twice a day, every other day, You can take it every other week, every other month, etc.
본 발명의 세이지 추출물 및 서양고추나물 추출물을 포함하는 조성물은 항산화, 항염증(NO 저해, IL-6 억제, TNF-alpha 억제), 뇌신경세포 보호 및 아세틸콜린에스테라아제를 저해효과를 상승시킴에 따라, 기억력 개선 및 인지기능 증진에 효과적이다. 또한 천연물 식의약소재로 실제 식품으로 섭취가 가능하고 부작용이 없으며, 농생물 자원을 활용해 신규 기능성 물질을 유용하게 사용될 수 있다.As the composition containing the sage extract and the horseradish extract of the present invention enhances antioxidant, anti-inflammatory (NO inhibition, IL-6 inhibition, TNF-alpha inhibition), brain nerve cell protection, and acetylcholinesterase inhibitory effects, It is effective in improving memory and enhancing cognitive function. In addition, as a natural food and drug material, it can be consumed as actual food and has no side effects, and new functional substances can be usefully used by utilizing agricultural biological resources.
도 1은 본 발명의 복합추출물의 총페놀 함량 증가 및 상승효과 결과를 나타낸 것이다.
도 2는 Scopolamine 처리 사멸유도에 대한 복합추출물(세이지+서양고추나물)의 뇌신경세포 보호 및 상승효과 확인 결과를 나타낸 것이다.
도 3은 H2O2 처리 사멸유도에 대한 복합추출물(세이지+서양고추나물)의 뇌신경세포 보호 및 상승효과 결과를 나타낸 것이다.
도 4는 복합추출물(세이지+서양고추나물)의 아세틸콜린에스테라아제 저해효과 증가 및 상승효과 확인 결과를 나타낸 것이다.Figure 1 shows the total phenol content increase and synergistic effect results of the composite extract of the present invention.
Figure 2 shows the results of confirming the brain nerve cell protection and synergistic effect of the composite extract (sage + western pepper herb) on the induction of scopolamine treatment death.
Figure 3 shows the results of the brain nerve cell protection and synergistic effect of the composite extract (sage + western pepper herb) for the induction of death by H 2 O 2 treatment.
Figure 4 shows the results of confirming the increase in the acetylcholinesterase inhibitory effect and the synergistic effect of the composite extract (sage + western pepper herb).
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by examples and experimental examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following Examples and Experimental Examples.
<실시예 1> 세이지 및 서양고추나물 복합추출물의 제조<Example 1> Preparation of sage and capsicum herb complex extract
건조 후 분쇄한 세이지 잎 및 서양고추나물의 꽃, 잎, 열매를 각각 10g에 70%(v/v) 발효주정을 용매로 사용하여 각각 140 mL을 첨가하고 60℃에서 2시간 동안 추출한 후 760g에서 20분간 원심분리한 상등액을 6 μm filter paper로 여과하였다. 이후, 감압농축 및 동결건조 후 분말화하여 각각의 추출물을 제조하였다. 이후, 세이지 추출물 및 서양고추나물 추출물을 최적의 배합비율 1:1의 동량비(중량비)로 상호 보완적으로 상승 작용할 수 있도록 혼합 조성하여 복합 추출물을 실험에 사용하였다.After drying, 140 mL of each of 10 g of pulverized sage leaves and flowers, leaves, and fruits of horseradish was added using 70% (v/v) fermented alcohol as a solvent, extracted at 60 ° C for 2 hours, and then heated at 760 g. The supernatant centrifuged for 20 minutes was filtered with 6 μm filter paper. Thereafter, each extract was prepared by powdering after concentration under reduced pressure and lyophilization. Thereafter, the combination of sage extract and capsicum extract was used in the experiment by mixing the sage extract and the western pepper herb extract in an equal amount ratio (weight ratio) of 1:1 so that they could act synergistically and complement each other.
<실험예 1> 항산화 활성 평가: 총 페놀 함량(TPC) 평가<Experimental Example 1> Antioxidant activity evaluation: total phenol content (TPC) evaluation
총 페놀성 화합물 함량은 Folin-Denis법에 의해 비색 정량하였다. 원심분리한 시료 1 mL에 0.2M phenol reagent 1 mL를 첨가하여 3분 동안 실온에서 방치한 후 2% Na2CO3용액 1 mL를 첨가하여 실온에서 1시간 방치한 다음 UV spectrophotometer를 사용하여 750 nm에서 흡광도를 측정하여 gallic acid를 표준물질로 사용하여 상기의 방법으로 적성한 표준곡선으로부터 총 페놀을 gallic acid의 양으로 환산하였다. 추출물 10 mg/ml에 대한 총페놀 함량을 측정한 결과, 각각의 단독추출물(세이지 530μg/ml, 서양고추나물 446μg/ml)에 비해 복합추출물(598μg/ml, 세이지+서양고추나물))에서 총페놀 함량이 증가하여 복합추출물의 상승효과를 확인하였다(도 1).Total phenolic compound content was quantified colorimetrically by the Folin-Denis method. Add 1 mL of 0.2M phenol reagent to 1 mL of the centrifuged sample, leave it at room temperature for 3 minutes, add 1 mL of 2% Na 2 CO 3 solution, leave it at room temperature for 1 hour, and then use a UV spectrophotometer to measure 750 nm The absorbance was measured and the total phenol was converted into the amount of gallic acid from the standard curve prepared by the above method using gallic acid as a standard material. As a result of measuring the total phenol content for 10 mg/ml of the extract, the total amount of total phenol content in the combined extract (598μg/ml, sage + red pepper herb) compared to each single extract (sage 530μg/ml, horseradish herb 446μg/ml) As the phenol content increased, the synergistic effect of the composite extract was confirmed (FIG. 1).
<실험예 2> 본 발명의 기억력/인지능력 개선 평가<Experimental Example 2> Memory/cognitive ability improvement evaluation of the present invention
2-1. 뇌신경세포 보호효과(MTT) 2-1. Brain nerve cell protective effect (MTT)
본 실험에서 사용한 인체유래 SH-SY5Y 신경세포는 한국세포주은행에서 구입하여 사용하였다. SH-SY5Y 신경세포는 10% fetal bovine serum, 100 U/mL penicillin 및 streptomycin이 포함된 Dulbecco’s modified Eagle’s medium(Gibco BRL.,Gaithersburg, MD, USA)을 사용하여 37℃, 5% CO2 조건에서 배양하였다. 추출물의 신경세포 사멸에 대한 보호 효과를 알아보기 위하여 SH-SY5Y 세포는 96well plate에 6×104cells/well로 동일하게 분주하여 24시간 배양한 후, 시료들을 각 농도에 따라 처리하였다. 1시간 후, 신경세포 사멸을 유도하는 scopolamine 5 mM 또는 H2O2 150μM를 첨가하여 24시간 배양하였다. 이후, 5 mg/ml MTT 10 μl를 각 well에 분주 한 후 37℃ 배양기에서 3시간 동안 빛에 노출되지 않게 배양하였다. 상등액을 제거하고 DMSO 50 μl를 넣어 37 ℃에서 10분 반응시킨 후, 570 nm에서 흡광도를 측정하였다. 측정한 formazan 생성 정도는 정상세포에서의 측정값과 비교하여 백분율(%)로 표시하였다.Human-derived SH-SY5Y neurons used in this experiment were purchased from the Korea Cell Line Bank. SH-SY5Y neurons were cultured at 37°C and 5% CO 2 using Dulbecco's modified Eagle's medium (Gibco BRL., Gaithersburg, MD, USA) containing 10% fetal bovine serum, 100 U/mL penicillin and streptomycin. did In order to examine the protective effect of the extract against neuronal cell death, SH-SY5Y cells were equally divided into 6×10 4 cells/well in a 96-well plate, cultured for 24 hours, and samples were treated according to each concentration. After 1 hour, 5 mM scopolamine or 150 μM H 2 O 2 , which induces neuronal cell death, was added and cultured for 24 hours. Thereafter, 10 μl of 5 mg/ml MTT was dispensed into each well and incubated in a 37° C. incubator without exposure to light for 3 hours. After removing the supernatant, adding 50 μl of DMSO and reacting at 37 ° C. for 10 minutes, absorbance was measured at 570 nm. The measured formazan production level was expressed as a percentage (%) compared to the measured value in normal cells.
추출물 50 μg/ml 및 scopolamine 5 mM를 처리하여 뇌신경세포 보호효과를 측정한 결과, 각각의 단독추출물(세이지, 서양고추나물) 대비 복합추출물(세이지+서양고추나물)에서 우수한 뇌신경세포 보호 및 복합추출물의 우수한 상승효과를 확인하였다(도 2).As a result of measuring the protective effect on brain nerve cells by treating with 50 μg/ml of the extract and 5 mM of scopolamine, the combined extract (Sage + Western red pepper herb) showed excellent brain nerve cell protection and complex extract compared to each single extract (Sage, Western red pepper herb) The excellent synergistic effect of was confirmed (FIG. 2).
또한, 추출물 50 μg/ml 및 H2O2 150μM를 처리하여 뇌신경세포 보호효과를 측정한 결과, 각각의 단독추출물(세이지, 서양고추나물) 대비 복합추출물(세이지+서양고추나물)에서 우수한 뇌신경세포 보호 및 복합추출물의 우수한 상승효과를 확인하였다(도 3).In addition, as a result of measuring the protective effect of brain nerve cells by treating with 50 μg/ml of the extract and 150 μM of H 2 O 2 , the brain nerve cells were excellent in the composite extract (sage + Western pepper herb) compared to each single extract (sage, western red pepper herb) It was confirmed that the excellent synergistic effect of protection and composite extract (Fig. 3).
2-2. 아세틸콜린에스테라아제(Acetylcholinesterase) 저해효과2-2. Acetylcholinesterase inhibitory effect
아세틸콜린에스테라아제는 아세틸콜린을 파괴하여 신경전달을 억제하는 효소로 알려져 있다. 추출물의 아세틸콜린에스테라아제의 생성을 억제하는지 확인하기 위해 Acetylcholinesterase ELISA kit (CUSABIO)를 사용하여 측정하였다. SH-SY5Y 신경세포는 24well plate에 4×105cells/well로 동일하게 분주하여 24시간 배양한 후, 시료들을 각 농도에 따라 처리하였다. 1시간 후, 신경세포 사멸을 유도하는 scopolamine 5 mM를 첨가하여 24시간 배양한 후, 배양 상등액을 분리하였다. 세포의 상등액을 10배 희석하였고 standard를 두 배씩 희석하여 standard 0부터 7까지 만들었다. 희석한 sample과 standard를 100 μl씩 각 well에 넣고 2시간 동안 37℃에서 배양한 후 well의 액체를 제거하고 100 μl의 biotin-antibody와 함께 37℃에서 1시간 배양하였다. 결합하지 못한 항체를 제거하기 위해 wash buffer로 씻어낸 후 HRP-avidin 100 μl를 넣고 1시간 동안 37℃에서 배양하였으며 wash과정을 거쳤으며 TMB substrate를 넣고 30분의 37℃ 배양 후 stop solution을 넣고 450nm에서 흡광도를 측정하였다. 흡광도에 따른 아세틸콜린에스테라아제 농도로의 변환은 standard값에 따른 수식으로 변환하였다.Acetylcholinesterase is known as an enzyme that inhibits neurotransmission by destroying acetylcholine. In order to determine whether the extract inhibits the production of acetylcholinesterase, it was measured using an Acetylcholinesterase ELISA kit (CUSABIO). SH-SY5Y neurons were equally divided into 4×10 5 cells/well in a 24-well plate, cultured for 24 hours, and samples were treated according to each concentration. After 1 hour, 5 mM of scopolamine, which induces neuronal cell death, was added and cultured for 24 hours, and then the culture supernatant was separated. The cell supernatant was diluted 10-fold, and the standard was diluted 2-fold to make
추출물 50 μg/ml 및 scopolamine 5 mM를 처리한 세포 배양 상등액에서의 아세틸콜린에스테라아제 농도를 측정한 결과, 각각의 단독추출물(세이지, 서양고추나물)에 비해 복합추출물(세이지+서양고추나물)에서 아세틸콜린에스테라아제 저해효과 증가 및 복합추출물의 우수한 상승효과를 확인하였다(도 4).As a result of measuring the concentration of acetylcholinesterase in the cell culture supernatant treated with 50 μg/ml of the extract and 5 mM of scopolamine, the acetylcholinesterase concentration in the composite extract (Sage + Western red pepper herb) was higher than that of each single extract (Sage and Western red pepper herb). It was confirmed that the cholinesterase inhibitory effect increased and the excellent synergistic effect of the complex extract (FIG. 4).
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210067972A KR20220160170A (en) | 2021-05-27 | 2021-05-27 | Composition for improving memory and cognitive ability, comprising Salvia officinalis L. extract and Hypericum perforatum L. extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210067972A KR20220160170A (en) | 2021-05-27 | 2021-05-27 | Composition for improving memory and cognitive ability, comprising Salvia officinalis L. extract and Hypericum perforatum L. extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220160170A true KR20220160170A (en) | 2022-12-06 |
Family
ID=84407421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210067972A KR20220160170A (en) | 2021-05-27 | 2021-05-27 | Composition for improving memory and cognitive ability, comprising Salvia officinalis L. extract and Hypericum perforatum L. extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20220160170A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100626336B1 (en) | 2004-12-30 | 2006-09-21 | 한국 한의학 연구원 | Pharmaceutical compositions and functional food comprising Extract of Hypericum erectum |
KR20200104749A (en) | 2019-02-27 | 2020-09-04 | 종근당건강 주식회사 | Composition for preventing or treating muscular disease containing Salvia officinalis extract |
-
2021
- 2021-05-27 KR KR1020210067972A patent/KR20220160170A/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100626336B1 (en) | 2004-12-30 | 2006-09-21 | 한국 한의학 연구원 | Pharmaceutical compositions and functional food comprising Extract of Hypericum erectum |
KR20200104749A (en) | 2019-02-27 | 2020-09-04 | 종근당건강 주식회사 | Composition for preventing or treating muscular disease containing Salvia officinalis extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100382564B1 (en) | Herbal composition for prevention and treatment of alzheimer's disease | |
JP6773821B2 (en) | A composition for the prevention, amelioration or treatment of degenerative neurological diseases containing a mixed extract of mulberry and bukuryo skin. | |
KR20220156605A (en) | Application of Traditional Chinese Medicine Compositions in Preparation of Drugs for Treatment or Prevention of Coronavirus Infection | |
KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
KR20110075742A (en) | Cosmetic composition containing polygonum multiflorum extracts, jujube extracts and hibiscus manihot extracts for moisturizing skin | |
US20220072077A1 (en) | Composition for preventing or treating skin diseases comprising bridalwreath spirea | |
KR20110125832A (en) | Pharmaceutical composition containing leaves and fruits of phellodendron amurense | |
KR20220160170A (en) | Composition for improving memory and cognitive ability, comprising Salvia officinalis L. extract and Hypericum perforatum L. extract | |
KR100986975B1 (en) | Pharmaceutical composition for the treatment of atopic dermatitis | |
KR102564119B1 (en) | Composition for improving learning ability, cognitive function and memory, including evening primrose extract | |
US20090068292A1 (en) | Therapeutic herb cosmetic composition | |
TWI747444B (en) | Use of camellia chrysantha extract for improving anti-blue light damage effect | |
KR102258283B1 (en) | Inflammation or allergy treatment and improvement composition comprising a natural product fermentation complex extract as an active ingredient and a method of manufacturing the same | |
KR102403795B1 (en) | Composition for anti-allergy or anti-oxidation comprising hemp seed extract | |
KR101594034B1 (en) | Composition Comprising Extracts of Artemisia rubripes, Tubocapsicum anomalum and Camellia japonica (leaves) Improving Skin Allergy, Inflammation and Geriatric Odor | |
KR20220154964A (en) | Method of roasting camellia leaves and various uses of roasted camellia leaf extract | |
JP2020200320A (en) | Composition for preventing or treating nicotinism containing extract of liriope platyphylla as active ingredient | |
JP4197194B2 (en) | Oral administration agent for intercellular adhesion suppression | |
KR20110095765A (en) | Anti-allergic composition containing scrophularia buergeriana extract | |
KR101503792B1 (en) | Neuroprotective composition comprising extract or fractions of Vaccinium uliginosum as an active ingredient | |
KR101310655B1 (en) | Cosmetic composition which contains trapa japonica flerov. extraction as active compotnets and the preparation method thereof | |
KR20170004632A (en) | Wnt/-catenin Activity promoting composition of Wnt/-catenin signaling with Anthriscus sylvestris Hoffm extract | |
Engels et al. | European Elder. | |
KR20220161567A (en) | Composition for anti-inflammatory or antioxidant comprising Pueraria lobata Ohwi extract and Glycyrrhiza uralensis Fischer extract | |
KR102478898B1 (en) | Saururus chinensis extract using oriental processing and its use for external skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |